Lumida
/HRMY
⌘K
Harmony Biosciences Holdings Inc

Harmony Biosciences Holdings Inc

HRMY
$41.52USD+1.02%+0.42 today

MARKET CAP

2.4B

P/E (TTM)

16.7x

FWD P/E

DAY RANGE

$41 – $42

52W RANGE

$26
$43

AI Summary

Stalk
StalkMedium

HRMY remains in a Stage 2 advancing uptrend with rising EMAs, but a Bullish Exhaustion pattern signals weakening upside momentum and a likely pullback. Price is marginally retracing into the rising 9/21 EMA zone without clear breakdown, so execution is deferred. We will watch for a firm acceptance off the 9/21 EMA area for a buy aligned with the medium-term bullish structure.

  • Q2 revenue $261.3M (+30% YoY, +21% QoQ); net income $75.4M ($1.28 EPS)
  • $963M cash position funds pipeline and business development
  • Weak profitability factor warns of limited margin conversion
Full analysis →
STATEMENT·Income statement
USD · GAAP
METRICFY 2021FY 2022FY 2023FY 2024FY 2025TREND
Sales, Adj.$305.4M$437.9M$582.0M$714.7M$868.5M
YoY %+91.2%+43.4%+32.9%+22.8%+21.5%
P / Sales8.3x7.4x3.2x2.8x2.5x
EV / Sales8.3x7.5x3.3x2.6x2.1x
Gross Profit, Adj.$249.9M$354.4M$460.8M$557.9M$670.1M
YoY %+89.3%+41.8%+30.0%+21.1%+20.1%
Margin %81.8%80.9%79.2%78.1%77.2%
EV / Gross Profit10.2x9.2x4.1x3.4x2.7x
EBITDA, Adj.$106.4M$143.6M$216.4M$214.9M$233.8M
YoY %+290.7%+35.0%+50.7%-0.7%+8.8%
Margin %34.8%32.8%37.2%30.1%26.9%
EV / EBITDA23.9x22.7x8.7x8.7x7.9x
EBIT$87.5M$120.2M$192.0M$190.8M$208.5M
YoY %+415.3%+37.3%+59.8%-0.6%+9.2%
Margin %28.7%27.4%33.0%26.7%24.0%
EV / EBIT29.0x27.1x9.9x9.8x8.8x
Net Income$34.6M$181.5M$128.9M$145.5M$158.7M
YoY %+154.2%+424.5%-29.0%+12.9%+9.1%
Net Margin11.3%41.4%22.1%20.4%18.3%
EPS (GAAP)$0.58$2.97$2.13$2.51$2.71
YoY %+123.4%+412.1%-28.3%+17.8%+8.0%